UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Jetstar to Charge for Overhead Cabin Bags From February 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
LIVONIA, Mich., March 13, 2018 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that it will host a conference call and live audio webcast on Thursday, March 15, 2018 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2017 and to provide a business update.
| Thursday, March 15 at 4:30pm Eastern Time | |
| Domestic: | (844) 494-0188 |
| International: | +1 (425) 278-9114 |
| Conference ID | 2090268 |
| Webcast: | https://edge.media-server.com/m6/p/bxoocvxs |
A webcast replay will be available on the News & Events section of the Gemphire website for all interested parties following the call and will be archived and available for 90 days.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors. Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD. Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151. Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit www.gemphire.com for more information.
Contact:
Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
(646) 597-6987
Jeff Mathiesen, CFO
Gemphire Therapeutics Inc.
(734)-245-1700
